Musashi-2 (MSI2) regulation of DNA damage response in lung cancer

Author:

Bychkov IgorORCID,Deneka Alexander,Topchu Iuliia,Pangeni Rajendra P.,Lengner Christopher,Karanicolas John,Golemis Erica A.,Makhov Petr,Boumber Yanis

Abstract

AbstractLung cancer is one of the most common types of cancers worldwide. Non-small cell lung cancer (NSCLC), typically caused byKRASandTP53driver mutations, represents the majority of all new lung cancer diagnoses. Overexpression of the RNA-binding protein (RBP) Musashi-2 (MSI2) has been associated with NSCLC progression. To investigate the role of MSI2 in NSCLC development, we compared the tumorigenesis in mice with lung-specificKras-activating mutation andTrp53deletion, with and withoutMsi2deletion (KP versus KPM2 mice). KPM2 mice showed decreased lung tumorigenesis in comparison with KP mice what supports published data. In addition, using cell lines from KP and KPM2 tumors, and human NSCLC cell lines, we found that MSI2 directly bindsATM/AtmmRNA and regulates its translation. MSI2 depletion impaired DNA damage response (DDR) signaling and sensitized human and murine NSCLC cells to treatment with PARP inhibitorsin vitroandin vivo. Taken together, we conclude that MSI2 supports lung tumorigenesis, in part, by direct positive regulation of ATM protein expression and DDR. This adds the knowledge of MSI2 function in lung cancer development. Targeting MSI2 may be a promising strategy to treat lung cancer.SignificanceThis study shows the novel role of Musashi-2 as regulator of ATM expression and DDR in lung cancer.

Publisher

Cold Spring Harbor Laboratory

Reference51 articles.

1. World Health O. 2020 December. Source: Globocan 2020. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf>. Accessed 2022 December.

2. Non-small cell lung cancer;Nature Reviews Disease Primers,2015

3. Somatic mutations affect key pathways in lung adenocarcinoma

4. Targeted therapies for treatment of non-small cell lung cancer—Recent advances and future perspectives;International Journal of Cancer,2016

5. Treating KRAS-mutant NSCLC: latest evidence and clinical consequences;Ther Adv Med Oncol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3